Hollyhigh International Capital: A Leading Chinese Investment Bank in Healthcare M&A

Hollyhigh International Capital is a leading Chinese investment bank that focuses on enterprise M&A across the healthcare industry. The company's core businesses include M&A, sales, financing consultation, buyout funds, and cross-border M&A. Hollyhigh aims to develop into a leading international investment bank that provides comprehensive services for healthcare enterprises' M&A and upgrades. The company's headquarters are located at Jia Tai International Building A, No.41 East Fourth Ring Middle Road, Chaoyang District, Beijing 100025, China.

The majority of Hollyhigh's core team members graduated from top Chinese and international academies such as Tsinghua, Peking University School of Pharmaceutical Sciences (SPS), China Pharmaceutical University, and Imperial College London. Mr. James Chen, the company's founder, graduated from Tsinghua University School of Economics and Management and was rated as one of the most influential investment bankers by “Talents” Magazine in 2003 and became the president of China's M&A Elite Club in 2006. Hollyhigh has gathered many professional, experienced, and motivated members in fields such as pharmaceutical investment, investment banks, finance, and law. At present, it has more than 50 employees.

In 2015, Hollyhigh accelerated the implementation of the “Apollo Program” using ApolloBio (430187, a National Equities Exchange and Quotations [NEEQ] Company) as a platform. By raising funds of less than 3 billion yuan, it invests in new pharmaceuticals in phase III clinical trials in the United States and gains the exclusive rights to develop, produce, and sell them in the Chinese market. This is a significant breakthrough in the Chinese biological medicine innovation model.

For more information about Hollyhigh International Capital, please visit their website at http://www.hollyhigh.cn.